Building a Best-In-Industry Oral Immunology Pipeline
             Potential                                                                           Upcoming
                                  IND-Enabling          Phase 1    Phase 2    Phase 3
            Indications                                                                          Milestones
Immunology - Wholly-Owned Oral Small Molecule Degraders

          AD, Asthma, COPD,                       KT-621 – AD
                                                                                          Ph2b AD Data: By mid-2027
STAT6     EoE, CRSwNP, CSU,
                                                                                          Ph2b Asthma Data: Late-2027
          PN, BP, others                         KT-621 – Asthma

          Lupus, Sjögren's, RA,                                                           Ph1 HV Start: 1Q26
IRF5      IBD, SSc, DM, others        KT-579                                              Ph1 HV Data: 2H26

Partnered Programs

          HS, AD, RA, Asthma,        KT-4851
IRAK4     IBD, others2
                                                                                           Ph1 Start: 2026

CDK23     Breast cancer and       Molecular
          other solid tumors        Glue

          Combining the convenience of oral drugs and the activity of biologics to expand access to
                  systemic advanced therapies for millions of patients around the world

                                                                                                                   11
